Sun Pharma Q3FY22 Results: PAT jumps 11% to Rs 2,059 cr, revenue up 12% YoY; stock trading flat

The pharmaceutical major Sun Pharma reported strong third-quarter earnings for the financial year 2021-22 (Q3FY22) on Monday. Both the topline and bottom line of the company swelled in double-digit figures on a year-on-year basis. However, the margins saw a minor dip during the quarter. 

Sun Pharma registered over an 11 per cent jump in the consolidated profit to Rs 2,059 crore during the October-December quarter of FY22 as compared to Rs 1,852 crore in the same quarter a year ago. 

See Zee Business Live TV Streaming Below:

Similarly, the company’s consolidated revenue also grew by 11.6 per cent to Rs 9863 crore as against Rs 8836 crore in the corresponding quarter of the previous fiscal. 

The EBITDA (earnings before interest, taxes, depreciation, and amortization) of Sun Pharma came at Rs 2606 crore, up 8.3 per cent YoY. In comparison, the EBITDA in Q3FY21 had come at Rs 2406 crore. 

While the margins of the company contracted by 60 basis points to 26.4 per cent in the third quarter of FY22 from 27 per cent in a year ago quarter. 

The stock of the company showed a sharp spike after company announced its Q3 results, however, it is at off highs after Q3 EBITDA margin comes in slightly lower than estimated. At around 02:14 pm, the stock is trading flat with positive bias at Rs 827.8 per share on the BSE.